Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.

Krismann, M.; Todt, B; Schröder, Jens‐M.; Gareis, D; Müller, K.-M.; Seeber, S.; Schütte, J.

doi:10.1200/jco.1995.13.11.2769

Cited by 176 publications

(90 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, PGP-9.5 (Norris et al, 1994), prostate-specific antigen , cytokeratin 19 (Krismann et al, 1995) and tyrosinase transcripts (Foss et al, 1995) can be amplified from peripheral blood of healthy volunteers. Illegitimate transcription of EGP2 may also be the explanation of the positive results obtained by us in bone marrow and peripheral stem cell harvests of patients suffering from various haematological malignancies.…”

Section: Discussionmentioning

confidence: 99%

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood

Helfrich¹,

tenPoele²,

Meersma³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary The presence of tumour cells in the circulation may predict disease recurrence and metastasis. To improve on existing methods of cytological or immunocytological detection, we have developed a sensitive and quantitative technique for the detection of carcinoma cells in blood, using the reverse transcriptase polymerase chain reaction (RT-PCR) identifying transcripts of the pancarcinoma-associated tumour marker EGP-2 (KSA or 17-lA antigen). The amount of EGP2 mRNA was quantified using an internal recombinant competitor RNA standard with known concentration and which is both reversely transcribed and co-amplified in the same reaction, allowing for a reliable assessment of the initial amount of EGP2 mRNA in the sample. Calibration studies, seeding blood with MCF-7 breast carcinoma cells, showed that the assay can detect ten tumour cells among 1.0 x 106 leucocytes. The PCR assay revealed that normal bone marrow expresses low levels of EGP2 mRNA, although immunocytochemistry with the anti-EGP2 MAb MOC31 could not identify any positively stained cell. Analyses using this RT-PCR assay may prove to have applications to the assessment of circulating tumour cells in clinical samples.

show abstract

Section: Discussionmentioning

confidence: 99%

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood

Helfrich¹,

tenPoele²,

Meersma³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The main problem of RNA-based assays continues to be the almost universally present background signal (Traweek et al, 1993;Datta et al, 1994;Burchill et al, 1995;Krismann et al, 1995;Fields et al, 1996;Moscinski et al, 1996;Mapara et al, 1997;Zippelius et al, 1997). We have recently developed a method that overcomes these problems by making use of two relatively recent developments.…”

mentioning

confidence: 99%

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

et al. 2003

View full text Add to dashboard Cite

We investigated the prognostic significance of circulating breast cancer cells in peripheral blood detected by quantitative RT-PCR of marker genes in patients with advanced breast cancer. Blood samples from 94 breast cancer patients with metastatic disease (M1) were examined for circulating tumour cells by studying the mRNA expression of CK19, p1B, PS2 and EGP2 by real-time PCR. Using a score function, developed for predicting circulating tumour cells by quadratic discriminant analysis (QDA), the four expression levels were combined into a single discriminant value. Tumour cells were present in 24 out of 94 (31%) of the patients. In 77% (72 out of 94) of the patients distant metastatic disease was localised in the bone. In 36% (26 out of 72) of the patients with bone metastases at the time of blood sampling, a positive QDA for the four genes was found, in contrast to only 14% (three out of 22) without bone involvement. Overall survival rates by Kaplan-Meier revealed no prognostic effect for the presence of bone metastases (P ¼ 0.93). However, patients with a positive QDA value did have a progression-free survival at 1 year of 3% and overall survival at 2 years of 17%, against 22 and 36% for patients with a negative QDA value (P ¼ 0.015 and 0.0053, respectively). Breast cancer patients with metastatic disease have a significantly worse progression-free and overall survival when circulating tumour cells can be detected in their peripheral blood.

show abstract

“…14 However, it has been demonstrated that PCR-based techniques are prone to false positive results and thus of limited value for detection of haematogenous epithelial cancer dissemination. 15,16 Controversial results have been also reported in non-epithelial solid tumours. 17,18 We have developed a highly specific, less time consuming and technically simpler RT-PCR assay capable of detecting epithelial cells that would otherwise go undetected by presently available ICC methods.…”

mentioning

confidence: 99%

Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results

Battaglia

Pedrazzoli

Palermo

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.

Cited by 176 publications

References 19 publications

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results

Contact Info

Product

Resources

About